It has been shown that inhibition of Src, either pharmacologically by Src inhibitor or through expression of a Src dominant-negative fusion construct, increased the cytotoxicity of paclitaxel or cisplatin, in both mouse and human cancer cells [21, 40, 42]. Here, SRC is linked to cancer.